Impact Factor
4.60
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
11.72
1,898 total citations
h5-index
62
h5 depth signal
Cited share
89.8%
149 of 166
Total citations
1,898
Citation footprint
Metric signal
9.90
External metric anchor
Self-citation
1.7%
32 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
550
Canada
98
Germany
93
United Kingdom
68
Italy
65
Citing Fields of Research
Dermatology
565
Allergies
256
Musculoskeletal Disorders
146
Immunology
98
Auto-Inflammatory Disorders
86
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,835
Articles tracked across the journal lifetime
Indexed publication set
166
149 cited publications
Last 12 months
85
7.1 publications/month
Open access share
56.5%
48 OA publications in the last year
Leading citing country
United States
550 citing publications
Leading citing field
Dermatology
565 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan.-Feb. 2000-
v1n1, Jan.-Feb. 2000-
Active Coverage
Research Focus & Classification
Indexed Subjects
Dermatology
Allergies
Musculoskeletal Disorders
Broad Categories
Dermatology
Allergies
Musculoskeletal Disorders
MeSH Descriptors
Cosmetic Techniques
Dermatologic Agents
Skin Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s40257-026-01080-9
Open DOI
From MAPK Reactivation to Response: Clinical Approaches Targeting BRAF/MEK Resistance in Melanoma
02
03
DOI 10.1007/s40257-026-01075-6
Open DOI
Ritlecitinib: A Review in Severe Alopecia Areata
Ritlecitinib (Litfulo®) is an oral dual inhibitor of Janus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of kinases. It is approved in several countries worldwide for the treatment of severe al...
04
05
DOI 10.1007/s40257-026-01066-7
Open DOI
Rosacea in Patients with Skin of Color: Diagnosis and Management
06
DOI 10.1007/s40257-026-01069-4
Open DOI
Laser Therapy for Cutaneous Vascular Anomalies: Efficacy, Safety, and Innovations
07
DOI 10.1007/s40257-026-01068-5
Open DOI
Correction: Genomics of Primary and Metastatic Cutaneous Melanoma: A Systematic Review and Meta-Analysis
08
DOI 10.1007/s40257-026-01067-6
Open DOI
Sex Hormones in Psoriatic Disease: A Systematic Review
09
DOI 10.1007/s40257-026-01064-9
Open DOI
Cutaneous Aging in Skin of Color: A Narrative Review
Cutaneous aging is a complex biological process that follows a distinct trajectory in skin of color (Fitzpatrick skin types III–VI) compared with lighter skin types. While increased epidermal melanin provides partial photoprotection and ...
10
DOI 10.1007/s40257-026-01057-8
Open DOI
Efficacy and Safety of SSGJ-608 in Moderate-to-Severe Plaque Psoriasis: A Pivotal Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial
Background SSGJ-608 is a recombinant, humanized, immunoglobulin G1 monoclonal antibody that targets human interleukin-17A with high specificity and high affinity. Objective We aimed to evaluate the efficacy and safety of SSGJ-608 in pati...
Bibliographical & Catalog Notes
Title from cover.
Also available online; subscription required for access and full text.